Table 4.
Outcomes of renal sarcoidosis
| Outcomes | All Patients (n=43) |
|---|---|
| Sarcoidosis flare, n (%)a | 9 (2.1) |
| Dialysis required, n (%) | 3 (7.0) |
| Dialysis initiation after biopsy (d) | 23 (1–330) |
| Death, n (%)b | 4 (9.3) |
| Time from biopsy to death (yr) | 2.6 (0.7–4.6) |
| Recovery within 6 mo, n (%) | 37 (86.0) |
| Complete recovery | 32 (74.4) |
| Partial recovery | 5 (11.6) |
| Nonrecovery | 6 (14.0) |
| Composite outcomes, n (%)c | 17 (39.5) |
| CKD progression | 8 (18.6) |
| Deathb | 4 (5.5) |
| CKD onsetd | 3 (7.0) |
| ESKD or dialysis | 3 (7.0) |
Among the nine patients who experienced disease flare, seven resumed steroid therapy (with one patient additionally receiving methotrexate and hydroxychloroquine), one was treated with azathioprine, and one received methotrexate monotherapy. Clinical outcomes in flared patients were comparable to nonflared cases: 89% (8/9) achieved complete renal recovery within 6 months (versus 71% [24/34] in nonflared patients, P = 0.41), while 33% (3/9) showed CKD progression (versus 41% [14/34] in nonflared patients, P = 0.99).
One patient died 10 months after dialysis.
Among 26 patients without composite outcomes, 15 patients had CKD and their CKD did not progress, 11, including nine AKI and two with proteinuria, achieved normal renal function.
The three patients presented AKI at the time of biopsy.